{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:34:47Z","timestamp":1794252887128,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012152","name":"National Postdoctoral Program for Innovative Talents","doi-asserted-by":"publisher","award":["BX20250256"],"award-info":[{"award-number":["BX20250256"]}],"id":[{"id":"10.13039\/501100012152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172827"],"award-info":[{"award-number":["82172827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172835"],"award-info":[{"award-number":["82172835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010104","name":"Tianjin Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017937","name":"Tianjin Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M782219"],"award-info":[{"award-number":["2025M782219"]}],"id":[{"id":"10.13039\/100017937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijbiomac.2026.151525","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:20:48Z","timestamp":1774023648000},"page":"151525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Subtype-specific APOBEC enrichment links genomic instability to predict immunotherapy response in breast cancer subtypes"],"prefix":"10.1016","volume":"356","author":[{"given":"ZeWei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaQi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenBin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChunLan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XuChen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-019-0828-0","article-title":"Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151525_bb0010","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/cac2.12207","article-title":"Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020","volume":"41","author":"Lei","year":"2021","journal-title":"Cancer Commun. (Lond.)"},{"issue":"7403","key":"10.1016\/j.ijbiomac.2026.151525_bb0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/tbcr-24-31","article-title":"Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024","volume":"5","author":"Li","year":"2024","journal-title":"Transl Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151525_bb0025","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0030","article-title":"APOBEC3 mutagenesis drives therapy resistance in breast cancer","author":"Gupta","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/tbcr-24-15","article-title":"Expert consensus on the clinical application of immunotherapy in breast cancer: 2024","volume":"5","author":"Wang","year":"2024","journal-title":"Transl Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151525_bb0040","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0045","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0050","doi-asserted-by":"crossref","DOI":"10.1177\/11772719221078774","article-title":"Immune checkpoint inhibitors in triple negative breast cancer: the search for the optimal biomarker","volume":"17","author":"Qureshi","year":"2022","journal-title":"Biomark. Insights"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151525_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011040","article-title":"Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation","volume":"13","author":"Guo","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"Pt 2","key":"10.1016\/j.ijbiomac.2026.151525_bb0060","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semcancer.2017.11.003","article-title":"Breast cancer genomics and immuno-oncological markers to guide immune therapies","volume":"52","author":"Hammerl","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"6230","key":"10.1016\/j.ijbiomac.2026.151525_bb0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41588-023-01592-8","article-title":"The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance","volume":"56","author":"Caswell","year":"2024","journal-title":"Nat. Genet."},{"issue":"7463","key":"10.1016\/j.ijbiomac.2026.151525_bb0075","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151525_bb0080","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat. Genet."},{"issue":"7437","key":"10.1016\/j.ijbiomac.2026.151525_bb0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature11881","article-title":"APOBEC3B is an enzymatic source of mutation in breast cancer","volume":"494","author":"Burns","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151525_bb0090","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/ng.3378","article-title":"An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers","volume":"47","author":"Chan","year":"2015","journal-title":"Nat. Genet."},{"issue":"7920","key":"10.1016\/j.ijbiomac.2026.151525_bb0095","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41586-022-04972-y","article-title":"Mechanisms of APOBEC3 mutagenesis in human cancer cells","volume":"607","author":"Petljak","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151525_bb0100","first-page":"3205","article-title":"APOBEC3B expression and its prognostic potential in breast cancer","volume":"19","author":"Mao","year":"2020","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/2326-6066.CIR-21-0146","article-title":"APOBEC mutagenesis inhibits breast Cancer growth through induction of T cell-mediated antitumor immune responses","volume":"10","author":"DiMarco","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1604313","article-title":"APOBEC in breast cancer: a dual player in tumor evolution and therapeutic response","volume":"12","author":"Lu","year":"2025","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0115","first-page":"449","article-title":"Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer","volume":"18","author":"Xu","year":"2019","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151525_bb0120","first-page":"744","article-title":"APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival","volume":"12","author":"Wu","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151525_bb0125","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1186\/s12885-024-13105-9","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.151525_bb0135","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12032-022-01849-y","article-title":"Therapeutic landscape of advanced HER2-positive breast cancer in 2022","volume":"39","author":"Gupta","year":"2022","journal-title":"Med. Oncol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151525_bb0140","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2217\/fon-2021-0668","article-title":"How we treat HR-positive, HER2-negative early breast cancer","volume":"18","author":"Lopez-Tarruella","year":"2022","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40246-018-0150-x","article-title":"Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment","volume":"12","author":"Vural","year":"2018","journal-title":"Hum. Genomics"},{"issue":"7793","key":"10.1016\/j.ijbiomac.2026.151525_bb0150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13059-019-1850-9","article-title":"A benchmark of batch-effect correction methods for single-cell RNA sequencing data","volume":"21","author":"Tran","year":"2020","journal-title":"Genome Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151525_bb0160","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0165","article-title":"Projected global rise in breast cancer incidence and mortality by 2050","author":"Devi","year":"2025","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/bjc.2014.532","article-title":"Breast cancer incidence and mortality in a transitioning Chinese population: current and future trends","volume":"112","author":"Wong","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151525_bb0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molonc.2012.01.011","article-title":"The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities","volume":"6","author":"De Palma","year":"2012","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0185","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151525_bb0190","doi-asserted-by":"crossref","first-page":"517","DOI":"10.6004\/jnccn.2020.7543","article-title":"Durable complete response with immune checkpoint inhibitor in breast cancer with high tumor mutational burden and APOBEC signature","volume":"18","author":"Chumsri","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"7605","key":"10.1016\/j.ijbiomac.2026.151525_bb0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-023-01425-5","article-title":"APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential","volume":"16","author":"Butler","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151525_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020374","article-title":"APOBEC mutagenesis in cancer development and susceptibility","volume":"16","author":"Dananberg","year":"2024","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0210","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41467-020-14568-7","article-title":"APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy","volume":"11","author":"Driscoll","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0215","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512942","article-title":"HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy","volume":"8","author":"Triulzi","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40364-024-00653-2","article-title":"DNA damage response in breast cancer and its significant role in guiding novel precise therapies","volume":"12","author":"Li","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0225","article-title":"Homologous recombination deficiency across subtypes of primary breast cancer","volume":"7","author":"Yndestad","year":"2023","journal-title":"JCO Precis. Oncol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151525_bb0230","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1158\/2159-8290.CD-20-0725","article-title":"Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution","volume":"11","author":"Venkatesan","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2026.151525_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1477980","article-title":"Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium","volume":"15","author":"Nandi","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151525_bb0240","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151525_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: a great barrier in the age of cancer immunotherapy","volume":"13","author":"El-Sayes","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026014510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026014510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:23:51Z","timestamp":1783473831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026014510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S0141813026014510"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151525","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subtype-specific APOBEC enrichment links genomic instability to predict immunotherapy response in breast cancer subtypes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151525"}}